Comparative Pharmacology
Head-to-head clinical analysis: ETHINYL ESTRADIOL LEVONORGESTREL versus OGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHINYL ESTRADIOL LEVONORGESTREL versus OGEN.
ETHINYL ESTRADIOL; LEVONORGESTREL vs OGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and levonorgestrel suppresses gonadotropins (FSH and LH) from the anterior pituitary, inhibiting ovulation. Also increases cervical mucus viscosity and induces endometrial changes that reduce implantation likelihood.
Estrogen replacement therapy; binds to estrogen receptors, activating gene transcription leading to cell proliferation and differentiation in target tissues.
1 tablet (0.03 mg ethinyl estradiol / 0.15 mg levonorgestrel) orally once daily for 21 consecutive days, followed by 7 days of placebo
0.75 mg orally once daily, cyclically (3 weeks on, 1 week off) for moderate to severe vasomotor symptoms associated with menopause.
None Documented
None Documented
Ethinyl estradiol: ~13-27 hours (terminal); Levonorgestrel: ~16-33 hours (terminal). Clinically, steady-state is reached within 5-7 days; elimination half-life supports once-daily dosing with potential accumulation.
Terminal elimination half-life of estrone is approximately 10-24 hours (mean ~14 hours); clinical context: permits once-daily dosing.
Renal: Ethinyl estradiol ~40% as glucuronide and sulfate conjugates; levonorgestrel ~20% as metabolites. Fecal: Ethinyl estradiol ~60%; levonorgestrel ~80% via biliary excretion.
Renal elimination of conjugated metabolites (estrone sulfate, estradiol glucuronide) accounts for >95% of excretion; fecal elimination is <5%.
Category D/X
Category C
Estrogen
Estrogen